Skip to main content

Preclinical and Coclinical Studies in Prostate Cancer.

Publication ,  Journal Article
Chen, M; Pandolfi, PP
Published in: Cold Spring Harb Perspect Med
April 2, 2018

Men who develop metastatic castration-resistant prostate cancer (mCRPC) will invariably succumb to their disease. Thus there remains a pressing need for preclinical testing of new drugs and drug combinations for late-stage prostate cancer (PCa). Insights from the mCRPC genomic landscape have revealed that, in addition to sustained androgen receptor (AR) signaling, there are other actionable molecular alterations and distinct molecular subclasses of PCa; however, the rate at which this knowledge translates into patient care via current preclinical testing is painfully slow and inefficient. Here, we will highlight the issues involved and discuss a new translational platform, "the co-clinical trial project," to expedite current preclinical studies and optimize clinical trial and experimental drug testing. With this platform, in vivo preclinical and early clinical studies are closely aligned, enabling in vivo testing of drugs using genetically engineered mouse models (GEMMs) in defined genetic contexts to personalize individual therapies. We will discuss the principles and essential components of this novel paradigm, representative success stories and future therapeutic options for mCRPC that should be explored.

Duke Scholars

Published In

Cold Spring Harb Perspect Med

DOI

EISSN

2157-1422

Publication Date

April 2, 2018

Volume

8

Issue

4

Location

United States

Related Subject Headings

  • Receptors, Androgen
  • Prostatic Neoplasms, Castration-Resistant
  • Mice
  • Male
  • Humans
  • Drug Resistance, Neoplasm
  • Disease Models, Animal
  • Clinical Trials as Topic
  • Antineoplastic Combined Chemotherapy Protocols
  • Antineoplastic Agents, Immunological
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chen, M., & Pandolfi, P. P. (2018). Preclinical and Coclinical Studies in Prostate Cancer. Cold Spring Harb Perspect Med, 8(4). https://doi.org/10.1101/cshperspect.a030544
Chen, Ming, and Pier Paolo Pandolfi. “Preclinical and Coclinical Studies in Prostate Cancer.Cold Spring Harb Perspect Med 8, no. 4 (April 2, 2018). https://doi.org/10.1101/cshperspect.a030544.
Chen M, Pandolfi PP. Preclinical and Coclinical Studies in Prostate Cancer. Cold Spring Harb Perspect Med. 2018 Apr 2;8(4).
Chen, Ming, and Pier Paolo Pandolfi. “Preclinical and Coclinical Studies in Prostate Cancer.Cold Spring Harb Perspect Med, vol. 8, no. 4, Apr. 2018. Pubmed, doi:10.1101/cshperspect.a030544.
Chen M, Pandolfi PP. Preclinical and Coclinical Studies in Prostate Cancer. Cold Spring Harb Perspect Med. 2018 Apr 2;8(4).

Published In

Cold Spring Harb Perspect Med

DOI

EISSN

2157-1422

Publication Date

April 2, 2018

Volume

8

Issue

4

Location

United States

Related Subject Headings

  • Receptors, Androgen
  • Prostatic Neoplasms, Castration-Resistant
  • Mice
  • Male
  • Humans
  • Drug Resistance, Neoplasm
  • Disease Models, Animal
  • Clinical Trials as Topic
  • Antineoplastic Combined Chemotherapy Protocols
  • Antineoplastic Agents, Immunological